223 related articles for article (PubMed ID: 9240732)
1. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
[TBL] [Abstract][Full Text] [Related]
2. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates clodronate and etidronate in the prevention of ovariectomy-induced osteopenia in growing rats.
Lepola VT; Kippo K; Hannuniemi R; Laurén L; Virtamo T; Osterman T; Jalovaara P; Sellman R; Väänänen HK
J Bone Miner Res; 1996 Oct; 11(10):1508-17. PubMed ID: 8889851
[TBL] [Abstract][Full Text] [Related]
4. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.
Rossini M; Gatti D; Zamberlan N; Braga V; Dorizzi R; Adami S
J Bone Miner Res; 1994 Nov; 9(11):1833-7. PubMed ID: 7863833
[TBL] [Abstract][Full Text] [Related]
6. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
7. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
8. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women.
Gnudi S; Lisi L; Fini M; Malavolta N
Int J Tissue React; 2001; 23(1):33-7. PubMed ID: 11392061
[TBL] [Abstract][Full Text] [Related]
9. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
10. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
[TBL] [Abstract][Full Text] [Related]
11. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
12. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
13. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
14. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
15. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
16. [A one-year prospective study of disodium etidronate versus 17 beta estradiol in the prevention of postmenopausal osteoporosis].
Chaouat D; Belange G; Danan S; De Vernejoul MC; Faures Quenet B; Chaouat Y
Rev Rhum Ed Fr; 1993 May; 60(5):353-8. PubMed ID: 8167642
[TBL] [Abstract][Full Text] [Related]
17. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
18. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy.
Filipponi P; Pedetti M; Fedeli L; Cini L; Palumbo R; Boldrini S; Massoni C; Cristallini S
J Bone Miner Res; 1995 May; 10(5):697-703. PubMed ID: 7639104
[TBL] [Abstract][Full Text] [Related]
19. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
Cosman F; Nieves J; Shen V; Lindsay R
J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
[TBL] [Abstract][Full Text] [Related]
20. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]